Overlapping its role in osteoimmunopathologies, the RANKL/RANK signaling axis is essential for malignant progression of many diverse cancers—multiple myeloma [9], non-small cell lung cancer[10], renal cell carcinomas [11], prostate [12, 13], and breast cancer [14–19]—to a metastatic state. This evidence concerns the gene TNFRSF11A and breast cancer.